ResMed Inc. (RMD) Revenue by Segment

ResMed revenue by segment at a glance

In Q3 fiscal 2026 (the quarter ended March 31, 2026), ResMed's largest business segment was Sleep and Breathing Health, with $1.26 billion or 88% of revenue, up 11.5% from a year earlier. Next: Residential Care Software (12%).

By product or service, Sleep and Breathing Health brought in 88% and Residential Care Software brought in 12% of revenue in Q3 fiscal 2026.

The fastest-growing business segment from a year earlier was Sleep and Breathing Health (+11.5%).

From company filings, in USD; latest quarter ended March 31, 2026; quarterly data from Q1 fiscal 2018.

ResMed Inc.

RMDHealthcare

United States

Healthcare

Revenue breakdown

Fiscal quarters, from company filings

Segments by quarter (USD)

Click a bar to see that period below. Striped bars are calculated fourth quarters; an empty slot means it could not be calculated on the same basis i

Sleep and Breathing HealthDevices and MasksSleep and RespiratoryResidential Care SoftwareSoftware As ServiceMasksSoftware As Service Before Deferred Revenue Adjustment

Q4 FY26 breakdown

Fiscal quarter ended Jun 30, 2026 · calculated (full year minus the other periods)

Item	Revenue	Share	vs year before	Trend
Sleep and Breathing Healthcalc	USD 1.29B	88.3%	+9.4%
Residential Care Softwarecalc	USD 171.92M	11.7%	+2.9%

Sum of items USD 1.46B. Shares are of the items shown. Click an item with › to see its parts.

Also reported by:

All periods

Every item and period in one grid. Purple = calculated; "–" = not available.

Item	Q4 FY26	Q3 FY26	Q2 FY26	Q1 FY26	Q4 FY25	Q3 FY25	Q2 FY25	Q1 FY25	Q4 FY24	Q3 FY24	Q2 FY24	Q1 FY24	Q4 FY23	Q3 FY23	Q2 FY23	Q1 FY23	Q4 FY22	Q3 FY22	Q2 FY22	Q1 FY22	Q4 FY21	Q3 FY21	Q2 FY21	Q1 FY21	Q4 FY20	Q3 FY20	Q2 FY20	Q1 FY20	Q4 FY19	Q3 FY19	Q2 FY19	Q1 FY19	Q4 FY18	Q3 FY18	Q2 FY18
Sleep and Breathing Health	1.3B	1.3B	1.3B	1.2B	1.2B	1.1B	1.1B	1.1B	1.1B	1.0B	1.0B	963.0M	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Devices and Masks	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	780.3M	674.9M	–	–	678.8M	679.9M	649.5M	594.2M	619.8M	582.3M	587.9M	540.8M	–	328.2M	337.0M
Sleep and Respiratory	–	–	–	–	–	–	–	–	–	–	–	–	–	980.1M	917.0M	844.4M	–	763.4M	795.8M	806.5M	–	–	708.2M	659.8M	–	–	–	–	–	–	–	–	–	–	–
Residential Care Software	171.9M	170.9M	166.9M	166.1M	167.0M	161.2M	156.5M	156.8M	151.9M	148.0M	144.9M	139.3M	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Software As Service	–	–	–	–	–	–	–	–	–	–	–	–	–	136.8M	116.8M	105.9M	–	101.1M	99.0M	97.5M	95.8M	93.8M	91.8M	92.1M	–	–	86.7M	86.9M	85.1M	79.9M	63.2M	–	–	39.9M	38.7M
Masks	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	223.5M	225.6M
Software As Service Before Deferred Revenue Adjustment	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	91.5M	89.6M	–	–	–	–	–	47.5M	–	–	–

ResMed revenue by business segment, last 4 quarters

Business segment	Q3 FY26	Q2 FY26	Q1 FY26	Q3 FY25	Share
Sleep and Breathing Health	$1.3B	$1.3B	$1.2B	$1.1B	88%
Residential Care Software	$170.9M	$166.9M	$166.1M	$161.2M	12%

In USD, fiscal quarters as reported; share = part of Q3 FY26 revenue.

ResMed revenue by product or service, last 4 quarters

Product or service	Q3 FY26	Q2 FY26	Q1 FY26	Q3 FY25	Share
Sleep and Breathing Health	$1.3B	$1.3B	$1.2B	$1.1B	88%
Residential Care Software	$170.9M	$166.9M	$166.1M	$161.2M	12%

In USD, fiscal quarters as reported; share = part of Q3 FY26 revenue.

Questions and answers

What are ResMed's business segments?

Sleep and Breathing Health and Residential Care Software (as reported for Q3 fiscal 2026).

Which business segment makes the most money for ResMed?

Sleep and Breathing Health: $1.26 billion, or 88% of revenue, in Q3 fiscal 2026.

What are ResMed's main products and services?

By revenue in Q3 fiscal 2026: Sleep and Breathing Health (88%) and Residential Care Software (12%).

MoreResMed stock overview ResMed financials ResMed executive team ResMed shareholders

Disclaimer: This analysis is for informational and educational purposes only and does not constitute financial, investment, tax, or legal advice. Data may be incomplete, delayed, or contain inaccuracies. Consult with a qualified financial advisor before making any investment decisions.